27 September 2022 - Iheezo represents the first approved use in the US ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anaesthetic approved for the US ophthalmic market in nearly 14 years.

Harrow today announced the US FDA approval of Iheezo (chloroprocaine hydrochloride 3% ophthalmic gel) for ocular surface anaesthesia.

Read Harrow press release